Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 7681 results

  1. Ublituximab for treating relapsing multiple sclerosis [ID6350]

    In development [GID-TA11268] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Tirzepatide for managing overweight and obesity [ID6179]

    In development [GID-TA11156] Expected publication date: 19 December 2024

    Technology appraisal guidance
    In development

  3. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Awaiting development [GID-TA11343] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]

    In development [GID-TA11570] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  5. Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia

    In development [GID-IPG10268] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  6. MRI-guided focused ultrasound subthalamotomy for treating Parkinson's

    In development [GID-IPG10402] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  7. MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's

    In development [GID-IPG10375] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  8. Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TS ID 12048]

    Awaiting development [GID-TA11629] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Human immunoglobulin with recombinant human hyaluronidase for maintenance treatment of multifocal motor neuropathy in people of any age TSID 12033

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

      Status ...

    Technology appraisal guidance
    Topic selection

  12. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development [GID-TA11501] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TS ID 12096]

    Awaiting development [GID-TA11627] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346

    In development [GID-TA11405] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development [GID-TA11096] Expected publication date: TBC

    Technology appraisal guidance
    In development